Monte Rosa Therapeutics (GLUE) Revenue & Revenue Breakdown
Monte Rosa Therapeutics Revenue Highlights
Latest Revenue (Q)
$4.70M
Monte Rosa Therapeutics Revenue by Period
Monte Rosa Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | - |
Monte Rosa Therapeutics generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Monte Rosa Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $4.70M | 341.26% |
| 2024-03-31 | $1.06M | -87.84% |
| 2023-12-31 | $8.75M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | - |
Monte Rosa Therapeutics generated $4.70M in revenue during Q2 2024, up 341.26% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Monte Rosa Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| KYMR | Kymera Therapeutics | $78.59M | $10.29M |
| NRIX | Nurix Therapeutics | $76.99M | $12.09M |
| FHTX | Foghorn Therapeutics | $34.16M | $6.89M |
| HOWL | Werewolf Therapeutics | $19.94M | $742.00K |
| IKNA | Ikena Oncology | $9.16M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| GBIO | Generation Bio | $5.90M | $4.06M |
| STTK | Shattuck Labs | $1.66M | $1.61M |
| LYEL | Lyell Immunopharma | $130.00K | $3.00K |
| DSGN | Design Therapeutics | - | - |
| GRCL | Gracell Bio | - | - |
| NKTX | Nkarta | - | - |
| ERAS | Erasca | - | - |
| SANA | Sana Bio | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
GLUE Revenue FAQ
What is Monte Rosa Therapeutics’s yearly revenue?
Monte Rosa Therapeutics's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. GLUE's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Monte Rosa Therapeutics’s quarterly revenue?
Monte Rosa Therapeutics's quarterly revenue for Q2 2024 was $4.7M, a 341.26% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $1.06M, a -87.84% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). GLUE's quarterly revenue for Q4 2023 was $8.75M, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is Monte Rosa Therapeutics’s revenue growth rate?
Monte Rosa Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.